Canakinumab
Ilaris (canakinumab) is an antibody pharmaceutical. Canakinumab was first approved as Ilaris on 2009-06-17. It is used to treat cryopyrin-associated periodic syndromes, familial mediterranean fever, juvenile arthritis, and mevalonate kinase deficiency in the USA. It has been approved in Europe to treat cryopyrin-associated periodic syndromes, gouty arthritis, and juvenile arthritis. The pharmaceutical is active against interleukin-1 beta.
| Trade Name | Ilaris |
|---|---|
| Common Name | Canakinumab |
| Indication | cryopyrin-associated periodic syndromes, familial mediterranean fever, gouty arthritis, juvenile arthritis, mevalonate kinase deficiency |
| Drug Class | Monoclonal antibodies: interleukins as targets|monoclonal antibodies: fully human, neural indications |
